Full Press Release Details
Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with
Non-Active Secondary Progressive Multiple Sclerosis
YORK, June 5, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology
company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced a reduction in microglial
activation as seen in 3-month Positron Emission Tomography (PET) scans that has now been seen in a total of 5 of the 6 patients
with non-active secondary-progressive multiple sclerosis (na-SPMS) treated with intranasal foralumab in its Expanded Access program.
Activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory diseases including multiple sclerosis,
Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
A reduction in microglial activation is associated with lowered inflammation
in the brain. Inflammation in the brain drives the disease pathology in multiple sclerosis. In SPMS, inflammation in the brain occurs
in microglia, the brain's immune cells, which drive the neurodegeneration of brain cells. During the inflammatory process associated
with SPMS, microglia are involved in the destruction of myelin, the protective sheath covering of nerve fibers, and contribute to the
formation of MS lesions.
Tarun Singhal, M.B.B.S., M.D., Director
of PET Imaging Program in Neurologic Diseases, associate neurologist and nuclear medicine physician at Brigham and Women's Hospital,
a founding member of Mass General Brigham Healthcare System, and Assistant Professor of Neurology at Harvard Medical School, commented,
"After review of the baseline and 3-month PET scans of the latest cohort of 4 Expanded Access patients, I have determined that 3
out of the 4 patients had a reduction in the microglial PET signal. An example of this can be seen in the graphic below, titled, "Figure
1", showing the deactivation of this signal in patient EA6. When combined with my assessment of the first 2 Expanded Access patients,
a total of 5 out of the 6 had a reduction in qualitative microglial PET signal, which appears to be clearly more significant than what
we have identified in our test-retest assessments. I look forward to studying more patients, with full quantitation, and particularly,
the next 4 patients in the Expanded Access program to see if this finding is replicated. We are preparing to submit the important results
from this trial for publication."
Howard L. Weiner, M.D., Chairman of Tiziana's
Scientific Advisory Board and Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital, a founding
member of Mass General Brigham Healthcare System, stated, "To see a reduction in microglial activation in 5 out of 6 na-SPMS patients
in only 3 months is extraordinary. This finding is even more remarkable because all of the 6 expanded access patients' na-SPMS had
clinically regressed on ocrelizumab treatment. I am excited to follow this program to see if the improvement in the 3-month PET scans
will translate to clinical improvement in the coming months."
Dr. Tanuja Chitnis, M.D., Principal Investigator
and Professor of Neurology at Harvard Medical School (HMS) and senior neurologist at Brigham and Women's Hospital, added, "There
are currently no FDA-approved treatments for na-SPMS. The reduction in microglial activation in the 3-month PET scans in 5 out of 6 patients
is truly encouraging and I look forward to getting the 3-month PET scans results of the next 4 Expanded Access patients later in 2023
and to starting the Phase 2a trial this year."
"I believe that Tiziana and Harvard
are at the forefront of research in neuroinflammatory diseases with unmet need," noted Gabriele Cerrone, Executive Chairman, Founder,
and acting Chief Executive Officer of Tiziana. "Our Phase 2a multi-center, double-blinded, placebo-controlled trial in na-SPMS uses
the 3-month PET scan as the primary outcome measure and our Expanded Access data from the first 6 patients give us increasing conviction
in the potential for a positive outcome. We believe this trial design will provide a quick validation of our intranasal foralumab asset
and will allow the company to proceed to the next clinical phase of development in na-SPMS."
KOL Webinar information:
Time: Monday, June 5, 2023 at 12:30 PM ET
Topic: Howard Weiner, M.D., will discuss anti-inflammatory approaches
in treating neurodegenerative disease and will provide an update on the ongoing intranasal foralumab Expanded Access program in na-SPMS
A live question and answer session will follow the formal presentations.
To register for the event, please click: https://lifescievents.com/event/tiziana/
Activated T cells play an important role
in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor and dampens
inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been
demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal foralumab Phase 2 trials
are expected to start in the third quarter of 2023 in patients with non-active SPMS. Immunomodulation by nasal anti-CD3 mAb represents
a novel avenue for treatment of inflammatory human diseases.1
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage
biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes
of immunotherapy. Tiziana's innovative nasal approach has the potential to provide an improvement
in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's lead candidate, intranasal
foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in
studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications pending
and is expected to allow for broad pipeline applications.
Forward-Looking Statements
Certain statements made in this announcement
are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current
expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as anticipates,' expects,' intends,'
plans,' believes,' 'seeks,' estimates,' and similar expressions are intended to identify forward-looking statements. These statements
are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are
beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted
in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance
on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking
statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake
any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated
events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development and Investor
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
LifeSci Advisors, LLC